I have been key in raising £2 million VC funding for Procarta’s research into its proprietary oligonucleotide antibacterials. As a director and CSO I am responsible for defining the business and IP strategy, as well as the scientific output and fund-raising, with successful applications in 2013 totalling £1.4 million. I received business training in 2008 as a RSE/BBSRC Enterprise Fellow. My role was recognised in 2010 when I was awarded ‘The Most Promising Innovator’ by the BBSRC. We are currently putting together a commercial collaboration to take our C. difficile and Gram-negative treatments into clinical trials.